New study suggests prostate screening should be done earlier, every two years

September 18, 2000

CHAPEL HILL - Although medical scientists still debate the effectiveness of prostate cancer screening known as serum prostate-specific antigen testing and even of prostate cancer treatments themselves, the PSA procedure is performed widely to detect the deadly illness earlier.

A new study conducted at the University of North Carolina at Chapel Hill suggests that current PSA screening strategies should be changed.

Former UNC-CH School of Public Health graduate student Kevin S. Ross, now a Johns Hopkins University medical student, found that testing men earlier likely would be more effective than waiting until age 50. To save money without increasing risks, testing should be done at ages 40 and 45 and every two years after age 50 instead of annually, the study showed.

A report on the research appears in the Sept. 20 issue of the Journal of the American Medical Association. Besides Ross, authors are Drs. Harry A. Guess, adjunct professor of epidemiology and biostatistics at UNC-CH; H. Ballentine Carter, professor of urology at Hopkins; and Dr. Jay D. Pearson of Merck Research Laboratories in Blue Bell, Pa., where Guess heads the epidemiology department.

The study involved computer analyses simulating the natural history of prostate cancer using different starting ages, testing intervals and PSA test result levels at which doctors encourage patients to have prostate tissue samples taken and checked for cancer. Computers allow researchers to tap existing information to create large numbers of patients artificially without the expense of massive clinical trials.

"Specifically, compared with no screening, the standard strategy prevents 3.2 deaths per 1,000 men with an additional 10,500 PSA tests and 600 prostate biopsies," the researchers wrote. "The earlier but less frequent strategy prevents 3.3 deaths per 1,000 men with an additional 7,500 PSA tests and 450 prostate biopsies."

New study suggests prostate screening should be done earlier, every two years

In other words, for every 1 million men, 3,200 lives would be saved under current practice when compared with no screening, the research suggests. With the strategy the researchers evaluated, 3,300 lives would be saved while requiring about 25 percent fewer PSA tests and biopsies.

"By doing a screen at age 40 and another one at age 45, you can often pick up people who are at high risk of cancer or who already have it and may need to be treated," Ross said. "Although the prevalence of prostate cancer is lower in 40- through 50-year-old men compared with older men, younger men with PSA-detected prostate cancers are more likely to have curable disease compared with older men whose cancers are detected by the tests."

Currently, PSA levels above 4 nanograms per milliliter trigger recommendations for biopsies, he said. Lowering that level would greatly increase the number of expensive biopsies done without significantly reducing the number of deaths

"This test is not a great predictor, but it's about the best thing we have at the moment," Ross said. "We are not trying to say screening should be done or that it should be done using our strategy. It's more like, if you are going to screen, our work suggests that the way we're doing it now isn't the best way."
-end-
Note: Guess can be reached through (919) 966-7415 or (610) 397-2539, hguess@sph.unc.edu .

University of North Carolina at Chapel Hill

Related Prostate Cancer Articles from Brightsurf:

Low risk of cancer spread on active surveillance for early prostate cancer
Men undergoing active surveillance for prostate cancer have very low rates - one percent or less - of cancer spread (metastases) or death from prostate cancer, according to a recent study published in the Journal of Urology®, an Official Journal of the American Urological Association (AUA).

ESMO 2020: Breast cancer drug set to transform prostate cancer treatment
A drug used to treat breast and ovarian cancer can extend the lives of some men with prostate cancer and should become a new standard treatment for the disease, concludes a major trial which is set to change clinical practice.

Major trial shows breast cancer drug can hit prostate cancer Achilles heel
A drug already licensed for the treatment of breast and ovarian cancers is more effective than targeted hormone therapy at keeping cancer in check in some men with advanced prostate cancer, a major clinical trial reports.

The Lancet: Prostate cancer study finds molecular imaging could transform management of patients with aggressive cancer
Results from a randomised controlled trial involving 300 prostate cancer patients find that a molecular imaging technique is more accurate than conventional medical imaging and recommends the scans be introduced into routine clinical practice.

Common genetic defect in prostate cancer inspires path to new anti-cancer drugs
Researchers found that, in prostate cancer, a mutation leading to the loss of one allele of a tumor suppressor gene known as PPP2R2A is enough to worsen a tumor caused by other mutations.

First prostate cancer therapy to target genes delays cancer progression
For the first time, prostate cancer has been treated based on the genetic makeup of the cancer, resulting in delayed disease progression, delayed time to pain progression, and potentially extending lives in patients with advanced, metastatic prostate cancer, reports a large phase 3 trial.

Men taking medications for enlarged prostate face delays in prostate cancer diagnosis
University of California San Diego School of Medicine researchers report that men treated with medications for benign prostatic hyperplasia (enlarged prostate) experienced a two-year delay in diagnosis of their prostate cancer and were twice as likely to have advanced disease upon diagnosis.

CNIO researchers confirm links between aggressive prostate cancer and hereditary breast cancer
The study has potential implications for families with members suffering from these types of tumours who are at an increased risk of developing cancer.

Distinguishing fatal prostate cancer from 'manageable' cancer now possible
Scientists at the University of York have found a way of distinguishing between fatal prostate cancer and manageable cancer, which could reduce unnecessary surgeries and radiotherapy.

Researchers find prostate cancer drug byproduct can fuel cancer cells
A genetic anomaly in certain men with prostate cancer may impact their response to common drugs used to treat the disease, according to new research at Cleveland Clinic.

Read More: Prostate Cancer News and Prostate Cancer Current Events
Brightsurf.com is a participant in the Amazon Services LLC Associates Program, an affiliate advertising program designed to provide a means for sites to earn advertising fees by advertising and linking to Amazon.com.